Anagrelide: a new drug for treating thrombocytosis.
Anagrelide is a member of the imidazo (2,1-b) quinazolin-2-one series of compounds, with a powerful antiaggregating effect on platelets. During studies in humans, anagrelide in small doses has produced thrombocytopenia. We therefore evaluated it in the treatment of thrombocytosis, and to date, platelet levels in 15 of 17 patients with primary thrombocythemia, 2 patients with polycythemia vera and thrombocytosis, and 1 patient with chronic granulocytic leukemia and thrombocytosis have been well controlled with the use of this agent. Induction doses of 1.0 to 1.5 mg given orally every six hours have produced a decrease in the platelet count, starting on day 5 and reaching a normal level by day 12. Side effects of anagrelide have been minimal. Maintenance therapy with 1.5 to 4.0 mg a day has continued to control the platelet count in patients for up to 28 months. This new agent appears promising in the treatment of thrombocytosis in patients with chronic myeloproliferative disease.
Silverstein
M N
MN
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
Petitt
R M
RM
Solberg
L A
LA
Fleming
J S
JS
Knight
R C
RC
Schacter
L P
LP
D000328:Adult; D000368:Aged; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D011087:Polycythemia Vera / Q000188:drug therapy; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000188:drug therapy; D013922:Thrombocytosis / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide